Volume 5 Issue 3, Sep 2020:
Perspective
The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma
Jianshu Wei,Yang Liu,Chunmeng Wang,Yajing Zhang,Chuan Tong,Guanghai Dai,Wei Wang
ORCID: orcid.org/0000-0001-7788-1895,John E. J. Rasko
ORCID: orcid.org/0000-0003-3181-7198,J. Joseph Melenhorst,Wenbin Qian
ORCID: orcid.org/0000-0002-9817-6674,Aibin Liang &…Weidong Han
ORCID: orcid.org/0000-0003-3207-3899
Chimeric antigen receptor T (CAR T) cell therapy has demonstrated efficacy in the treatment of haematologic malignancies. However, the accompanying adverse events, the most common of which is cytokine release syndrome (CRS), substantially limit its wide application. Due to its unique physiological characteristics, CRS in CAR T-cell treatment for B-cell non-Hodgkin lymphoma (B-NHL) may exhibit some special features. Although existing guidelines had greatly promoted the recognition and management of CRS, many recommendations are not fully applicable to B-NHL. Therefore, it is imperative to identify responses that are specific to CRS observed following CAR T treatment for B-NHL. Based on underlying biological processes and known pathophysiological mechanisms, we tentatively propose a new model to illustrate the occurrence and evolution of CAR T-cell-therapy-related CRS in B-NHL. In this model, tumour burden and bone marrow suppression are considered determinants of CRS. Novel phenomena after CAR T-cell infusion (such as local inflammatory response) are further identified. The proposed model will help us better understand the basic biology of CRS and recognize and manage it more rationally.
